Lysoway Therapeutics
Lysosomal ion channel modulators for neurodegenerative diseases
Cambridge, United States · Founded 2020
- Headquarters
- Cambridge, Massachusetts
- Employees
- 1–10
- Founded
- 2020
- Business Model
- B2B
- Website
- lysoway.com
About
Lysoway Therapeutics is a biotechnology company pioneering therapeutics targeting lysosomal ion channels for age-related neurodegenerative diseases. Based in Cambridge, Massachusetts and founded in 2020, the company develops potent small-molecule modulators of lysosomal ion channels such as TRPML1 and TMEM175, aiming to restore autophagy/lysosomal function to treat Parkinson's disease and rare diseases characterized by toxic cellular waste accumulation. Lysoway's lead program is a brain-penetrant, orally bioavailable TRPML1 agonist in preclinical/translational development, supported by grants from the Michael J. Fox Foundation.
Summary
Lysoway Therapeutics is a Biotech company based in Cambridge, United States, founded in 2020.
Tech & App Stack
2 technologies & apps tracked
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Biopharmaceutical services company
Specialty pharmaceutical company